000008271 001__ 8271
000008271 005__ 20240327094539.0
000008271 0247_ $$2DOI$$a10.6083/9p290b031
000008271 037__ $$aIR
000008271 041__ $$aeng
000008271 245__ $$aA single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients
000008271 260__ $$bOregon Health and Science University
000008271 269__ $$a2020
000008271 336__ $$aAbstract
000008271 520__ $$aThere are few studies that compare the safety of multiple induction therapies in simultaneous pancreas-kidney transplant (SPKT) patients. The purpose of this study is to compare basiliximab, thymoglobulin (ATG), and alemtuzumab according to HLA matching to assess allograft survival, rejection rate, and post-operative complications.
000008271 540__ $$fCC BY
000008271 542__ $$fIn copyright - joint owners
000008271 650__ $$aIron$$021036
000008271 650__ $$aDiabetes Mellitus$$017671
000008271 650__ $$aBasiliximab$$012802
000008271 650__ $$aAlemtuzumab$$012327
000008271 650__ $$aAllografts$$040445
000008271 6531_ $$aspk transplant
000008271 6531_ $$akidney-pancreas transplant
000008271 6531_ $$aabdominal organ transplant
000008271 6531_ $$athymoglobulin
000008271 7001_ $$aKhan, Lubna$$uOregon Health and Science University$$041354
000008271 7001_ $$aElstrott, Ben$$uOregon Health and Science University$$041354
000008271 7001_ $$aOlyaei, Ali$$uOregon Health and Science University$$041354
000008271 7001_ $$aLockridge, Joseph$$uOregon Health and Science University$$041354
000008271 7001_ $$aScott, David$$uOregon Health and Science University$$041354
000008271 711__ $$aResearch Week$$uOregon Health and Science University$$d2020
000008271 8564_ $$968dd0e9b-6648-47a6-a9a9-752160203ffc$$s50883$$uhttps://digitalcollections.ohsu.edu/record/8271/files/Lubna-Khan.pdf
000008271 8564_ $$9159ed99a-4247-47cc-862a-cfcba9f16f58$$s1162872$$uhttps://digitalcollections.ohsu.edu/record/8271/files/Khan_Presentation.pdf
000008271 905__ $$a/rest/prod/9p/29/0b/03/9p290b031
000008271 980__ $$aResearch Week